Haferkamp, Sebastian and Schilling, Bastian and Berking, Carola and Drexler, Konstantin and Gesierich, Anja and Tomsitz, Dirk and Erdmann, Michael and Jakob, Lea and Geissler, Edward K. and Zeman, Florian and Heinzerling, Lucie (2026) Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial. BRITISH JOURNAL OF DERMATOLOGY, 194 (2). pp. 216-224. ISSN 0007-0963, 1365-2133
Full text not available from this repository. (Request a copy)Abstract
Background Patients with BRAF wildtype metastatic melanoma who exhibit primary resistance to immune checkpoint inhibitors (ICIs) have a poor prognosis. Chemotherapy has been shown to induce genetic mutations, modify the tumour microenvironment and microbiome, and influence immune system activity.Objectives To investigate in a prospective multicentre phase II trial whether two applications of an alkylating agent (dacarbazine) can sensitize patients with metastatic melanoma who are nonresponsive to ICIs to the same checkpoint inhibitor regime.Methods The PROMIT trial (NCT04225390) enrolled patients with histologically confirmed BRAF wildtype metastatic melanoma who exhibited primary resistance to ICI therapy. Following radiological evidence of primary resistance to ICI (ipilimumab + nivolumab or pembrolizumab) upon the first staging after initiation, patients received two doses of dacarbazine at 850 mg m-2 intravenously on days 1 and 21. Subsequently, 1 week after application of the second dose of dacarbazine, patients were rechallenged with the same ICI therapy to which they had previously shown progressive disease.Results In total, 53 patients were enrolled across four German skin cancer centres. Of these patients, 38 were evaluable for efficacy, having received at least one dose of ICI re-exposure. The overall objective response rate was 18% (95% confidence interval 0.08-0.34), with 7 of 38 patients achieving a partial response. The disease control rate was 37%. Therapy was well tolerated, with treatment-related >= grade 3 CTCAE adverse events occurring in 10% of patients. No new safety signals were observed.Conclusions The study indicates that short-term chemotherapy followed by ICI rechallenge can overcome primary ICI resistance in patients with melanoma, supporting its potential as a new therapeutic option in clinical practice. Metastatic melanoma is a serious and aggressive form of skin cancer. It can spread to other parts of the body. Mutations in some genes (part of our DNA) can result in melanoma. One of these genes is called 'BRAF'. The treatment options are limited for patients whose melanoma does not have a mutation in the BRAF gene and who do not benefit from a type of therapy called 'immune checkpoint inhibitors' (ICIs).In this study, we aimed to find out whether a short course of chemotherapy could help these patients with melanoma benefit from ICI therapy. The study took place at four skin cancer centres in Germany. It included 38 patients with metastatic melanoma who had not responded to ICI treatment before. The patients received two doses of a chemotherapy drug called 'dacarbazine'. After this, they were treated again with the same ICI therapy that had previously not helped them. The aim was to see if this approach could improve their chances of benefiting from ICI treatment. The tumours shrank in 7 of the 38 patients. This is a result known as a 'partial response'. The cancer either shrank or stopped growing in 14 patients. The treatment was generally well tolerated. Serious side effects related to the treatment occurred in 17 patients (10%), but no unexpected safety concerns were reported.These findings suggest that a short course of chemotherapy may help some patients overcome resistance to immunotherapy. This approach could provide a new option for patients with melanoma who have limited treatment choices. Patients with BRAF wildtype metastatic melanoma who exhibit primary resistance to immune checkpoint inhibitors (ICIs) have limited treatment options. The multicentre PROMIT phase II trial (NCT04225390) investigated whether short-term chemotherapy with dacarbazine could resensitize these patients to the same ICI regimen. Following confirmation of primary resistance, patients received two doses of dacarbazine and were then re-exposed to ICIs. The objective response rate was 18% and the disease control rate was 37%. Treatment was well tolerated, with 10% of patients experiencing treatment-related adverse events of >= grade 3. These results suggest that intermittent dacarbazine treatment can overcome primary ICI resistance in a subgroup of patients and offer a potential therapeutic strategy.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ACQUIRED-RESISTANCE; ANTI-PD-1 THERAPY; T-CELLS; DACARBAZINE; BLOCKADE; SURVIVAL |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie Medicine > Lehrstuhl für Dermatologie und Venerologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 04 Nov 2026 07:01 |
| Last Modified: | 04 Nov 2026 07:01 |
| URI: | https://pred.uni-regensburg.de/id/eprint/66704 |
Actions (login required)
![]() |
View Item |

